Medicine:Rotavirus vaccine

From HandWiki
Short description: Vaccine used to protect against rotavirus infections
Rotavirus vaccine
Vaccine description
Target diseaseRotavirus
TypeAttenuated virus
Clinical data
Trade namesRotarix, RotaTeq, others
AHFS/Drugs.comMonograph
MedlinePlusa607024
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
ChemSpider
  • none
KEGG
 ☒N☑Y (what is this?)  (verify)

The rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children.[1] The vaccines prevent 15–34% of severe diarrhea in the developing world and 37–96% of the risk of death among young children due to severe diarrhea.[1] Immunizing babies decreases rates of disease among older people and those who have not been immunized.[2]

The World Health Organization (WHO) recommends that rotavirus vaccine be included in national routine vaccinations programs, especially in areas where the disease is common.[1] This should be done along with promoting breastfeeding, handwashing, clean water, and good sanitation.[1] It is given by mouth and requires two or three doses.[1] It should be given starting around six weeks of age.[1]

The vaccines are safe.[1] This includes their use in people with HIV/AIDS.[1] The vaccines are made from weakened rotavirus.[1]

The vaccine first became available in the United States in 2006.[3] It is on the World Health Organization's List of Essential Medicines.[4][5] As of 2013, there are two types of vaccine available globally, Rotarix and RotaTeq. Others are used in some countries.[1]

Medical uses

Effectiveness

A 2009 review estimated that vaccination against rotavirus would prevent about 45% of deaths due to rotavirus gastroenteritis, or about 228,000 deaths annually worldwide. At US$5 per dose, the estimated cost per life saved was $3,015, $9,951 and $11,296 in low-, lower-middle-, and upper-middle-income countries, respectively.[6]

Safety and efficacy trials in Africa and Asia found that the vaccines dramatically reduced severe disease among infants in developing countries, where a majority of rotavirus-related deaths occur.[7][8] A 2021 Cochrane systematic review concluded that Rotavac, RotaTeq, and Rotarix vaccines are safe and are effective at preventing diarrhea that is related to a rotavirus infection.[9]

Rotavirus vaccines are licensed in more than 100 countries, and more than 80 countries have introduced routine rotavirus vaccination.[10] The incidence and severity of rotavirus infections has declined significantly in countries that have acted on the recommendation to introduce the rotavirus vaccine.[11] In Mexico, which in 2006 was among the first countries in the world to introduce rotavirus vaccine, the diarrheal disease death rates from rotavirus dropped by more than 65% among children age two and under during the 2009 rotavirus season.[12] In Nicaragua, which in 2006 became the first developing country to introduce the rotavirus vaccine, investigators recorded a substantial impact, with rotavirus vaccine preventing 60% of cases against severe rotavirus and cutting emergency room visits in half.[13] In the United States, vaccination has reduced rotavirus-related hospitalizations by as much as 86% since 2006. In April 2016, the World Health Organization released statistics for the period of 2000–2013, which showed developing countries that have introduced rotavirus vaccines experienced significant decreases in deaths and hospitalizations from rotavirus diarrhea after introduction.[14][8]

Additionally, the vaccines may also prevent illness in non-vaccinated children by limiting exposure through the number of circulating infections.[2] A 2014 review of available clinical trial data from countries routinely using rotavirus vaccines in their national immunization programs found that rotavirus vaccines have reduced rotavirus hospitalizations by 49–92% and all-cause diarrhea hospitalizations by 17–55%.[15]

Schedule

The World Health Organization recommends the first dose of vaccine be given right after six weeks of age.[1]

Types

Rotarix

Rotarix vaccine for oral administration

Rotarix is a monovalent, human, live attenuated rotavirus vaccine containing one rotavirus strain of G1P[8] specificity. Rotarix is indicated for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) when administered as a 2-dose series in infants and children.[16] It was approved in Europe in 2006 and by the U.S. FDA in April 2008. It is administered by mouth.[17][18]

RotaTeq

H. Fred Clark and Paul Offit, the inventors of RotaTeq.

RotaTeq is a live, oral pentavalent vaccine that contains five rotavirus strains produced by reassortment. The rotavirus A parent strains of the reassortants were isolated from human and bovine hosts. Four reassortant rotaviruses express one of the outer capsid, VP7, proteins (serotypes G1, G2, G3, or G4) from the human rotavirus parent strain and the attachment protein VP4 (type P7) from the bovine rotavirus parent strain. The fifth reassortant virus expresses the attachment protein VP4, (type P1A), from the human rotavirus parent strain and the outer capsid protein VP7 (serotype G6) from the bovine rotavirus parent strain. In February 2006, the U.S. Food and Drug Administration approved RotaTeq for use in the United States. In August 2006, Health Canada approved RotaTeq for use in Canada.[19] Merck worked with a range of partners including governmental and non-governmental organisations to develop and implement mechanisms for providing access to this vaccine in the developing world,[20] an effort which was slated to come to an end in 2020.[21]

Rotavac

Rotavac was licensed for use in India in 2014, and is manufactured by Bharat Biotech International Limited. It is a live attenuated, monovalent vaccine containing a G9P[11] human strain isolated from an Indian child.[22] It is given by mouth in a three-dose series, four weeks apart, beginning at six weeks of age up until eight months of age.[23]

Rotavin-M1

Rotavin-M1 was licensed for use in Vietnam in 2007, and is manufactured by the Center for Research and Production of Vaccines. The vaccine contains a G1P[8] human rotavirus strain.[24]

Lanzhou lamb

Lanzhou lamb rotavirus vaccine was licensed for use in China in 2000, and is manufactured by the Lanzhou Institute of Biological Products. It contains a G10P[12] lamb rotavirus strain.[24]

Rotasiil

Rotasiil is a lyophilized pentavalent vaccine licensed for use in India in 2018. It contain human bovine reassortant strains of rotavirus serotypes G1, G2, G3, G4 and G9. This is world's first thermostable vaccine which can be stored without refrigeration at or below 25 °C. Rotasiil is manufactured by the Serum Institute of India.[25][26]

History

In 1998, a rotavirus vaccine (RotaShield, by Wyeth) was licensed for use in the United States. Clinical trials in the United States, Finland , and Venezuela had found it to be 80 to 100% effective at preventing severe diarrhea caused by rotavirus A, and researchers had detected no statistically significant serious adverse effects. However post-licensure studies conducted in the United States by Trudy Murphy and her colleagues at the Centers For Disease Control and Prevention (CDC) and Kramarz et al., found that Infants who received the vaccine were 30 times more likely to develop a severe form of bowel obstruction, called intussusception, during 3 to 7 days after the first dose than unvaccinated infants.[27][28] The excess risk was estimated between one case in 5,000 to 10,000 vaccinees. Based on these data, the Advisory Committee on Immunization Practices (ACIP) withdraw recommendation to use the vaccine,[29] and the manufacturer of the vaccine withdrew it from the market in 1999. There then followed eight years of delay until rival manufacturers were able to introduce new vaccines that were shown to be more safe and effective in children: Rotarix by GlaxoSmithKline[16] and RotaTeq by Merck.[30] Both are taken orally and contain disabled live virus.[3]

The World Health Organization recommends that rotavirus vaccine be included in all national immunization schedules because the risk of intussusception following rotavirus vaccination remains very low compared with the benefits of preventing the impact of severe and deadly diarrhoea.[31]

Society and culture

More than 80 countries have introduced routine rotavirus vaccination, almost half with the support of Gavi, the Vaccine Alliance.[24] In order to make rotavirus vaccines available, accessible, and affordable in all countries—particularly low- and middle-income countries in Africa and Asia where the majority of rotavirus deaths occur—international non-governmental organization PATH, the WHO, the U.S. Centers for Disease Control and Prevention (CDC), and Gavi have partnered with research institutions and governments to generate and disseminate evidence, lower prices, and accelerate introduction. These and other organizations continue to work to improve coverage and public health impact of rotavirus vaccination today.[citation needed]

Temporary suspension in the US

On 22 March 2010, the detection of DNA from porcine circovirus types 1 and 2 within RotaTeq and Rotarix prompted the FDA to suspend the use of rotavirus vaccines while conducting an investigation the finding of DNA from porcine circovirus-1 (PCV1) in the vaccine in collaboration with the 12 members of the Vaccines and Related Biological Products Advisory Committee (VRBPAC).[32] On 6 May 2010, the FDA announced its decision to revoke the suspension, stating that porcine circovirus types 1 and 2 pose no safety risks in humans and concluded that health risks involved did not offset the benefits of the vaccination.[32] In May 2010 the suspension of the Rotarix vaccine was lifted.[33]

Research

Doctors Without Borders (MSF) developed a heat-stable version named BRV-PV. Phase 3 of the clinical trials were completed in Niger on 31 December 2020.[34][35]

The vaccine has been associated with lower rates of type 1 diabetes.[36][37]

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 "Rotavirus vaccines. WHO position paper – January 2013". Relevé Épidémiologique Hebdomadaire 88 (5): 49–64. February 2013. PMID 23424730. 
  2. ↑ 2.0 2.1 "Real-world impact of rotavirus vaccination". The Pediatric Infectious Disease Journal 30 (1 Suppl): S1–S5. January 2011. doi:10.1097/INF.0b013e3181fefa1f. PMID 21183833. 
  3. ↑ 3.0 3.1 "Rotavirus Vaccine Live Oral". The American Society of Health-System Pharmacists. https://www.drugs.com/monograph/rotavirus-vaccine-live-oral.html. 
  4. ↑ World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO. 
  5. ↑ World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. WHO/MHP/HPS/EML/2021.02. 
  6. ↑ "Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries". The Journal of Infectious Diseases 200 (Suppl 1): S16–S27. November 2009. doi:10.1086/605026. PMID 19817595. 
  7. ↑ "Rotavirus vaccines: an update". Weekly Epidemiological Record 84 (51–52): 533–37. December 2009. 
  8. ↑ 8.0 8.1 "Health Impact of Rotavirus Vaccination in Developing Countries: Progress and Way Forward". Clinical Infectious Diseases 62 (Suppl 2): S91–S95. May 2016. doi:10.1093/cid/civ1015. PMID 27059361. 
  9. ↑ "Vaccines for preventing rotavirus diarrhoea: vaccines in use". The Cochrane Database of Systematic Reviews 2021 (11): CD008521. November 2021. doi:10.1002/14651858.CD008521.pub6. PMID 34788488. 
  10. ↑ "Rotavirus Deaths & Rotavirus Vaccine Introduction Maps—ROTA Council". http://rotacouncil.org/toolkit/rotavirus-burden-vaccine-introduction-map/. 
  11. ↑ "Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries". Human Vaccines 7 (7): 734–748. July 2011. doi:10.4161/hv.7.7.15511. PMID 21734466. 
  12. ↑ "Effect of rotavirus vaccination on death from childhood diarrhea in Mexico". The New England Journal of Medicine 362 (4): 299–305. January 2010. doi:10.1056/NEJMoa0905211. PMID 20107215. 
  13. ↑ "Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua". JAMA 301 (21): 2243–2251. June 2009. doi:10.1001/jama.2009.756. PMID 19491186. 
  14. ↑ "WHO | Estimated rotavirus deaths for children under 5 years of age: 2013, 215 000". http://www.who.int/immunization/monitoring_surveillance/burden/estimates/rotavirus/en/. 
  15. ↑ "Rotavirus vaccines in routine use". Clinical Infectious Diseases 59 (9): 1291–1301. November 2014. doi:10.1093/cid/ciu564. PMID 25048849. 
  16. ↑ 16.0 16.1 "Rotarix (RIX4414): an oral human rotavirus vaccine". Expert Review of Vaccines 6 (1): 11–19. February 2007. doi:10.1586/14760584.6.1.11. PMID 17280473. 
  17. ↑ "Approval Letter—Rotarix". U.S. Food and Drug Administration. 3 April 2008. https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm133920.htm. 
  18. ↑ "30. Rotavirus Vaccines". Vaccines. Elsevier Saunders. 2013. pp. 669–687. ISBN 978-1-4557-0090-5. https://books.google.com/books?id=hoigDQ6vdDQC&pg=PA669. 
  19. ↑ "RotaTeq Is Approved In Canada" (PDF) (Press release). Merck Frosst Canada. 23 August 2006. Archived from the original (PDF) on 2 October 2008. Retrieved 29 February 2008.
  20. ↑ "Project seeks to "fast track" rotavirus vaccine". Lancet 361 (9357): 582. February 2003. doi:10.1016/S0140-6736(03)12549-4. PMID 12598149. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)12549-4/fulltext. 
  21. ↑ "Merck Ends Delivery of Lifesaving Vaccines to Africa". OZY (Ozymandias.com). 2 November 2018. https://www.ozy.com/presidential-daily-brief/pdb-90376/supply-shortage-90393. 
  22. ↑ "Global Advisory Committee on Vaccine Safety, 11-12 June 2014". Weekly Epidemiological Record 89 (29): 321–36. 2014. 
  23. ↑ "ROTAVAC—Bharat Biotech". https://www.bharatbiotech.com/rotavac.html. 
  24. ↑ 24.0 24.1 24.2 Rota Council (2016). Rotavirus: Common, Severe, Devastating, Preventable. http://rotacouncil.org/wp-content/uploads/2016/03/White-paper-FINAL-v2.pdf. 
  25. ↑ "ROTASIIL" (in en). 17 July 2020. https://extranet.who.int/pqweb/content/rotasiil. 
  26. ↑ "Stability of heat stable, live attenuated Rotavirus vaccine (ROTASIIL®)". Vaccine 35 (22): 2962–2969. May 2017. doi:10.1016/j.vaccine.2017.04.025. PMID 28434688. 
  27. ↑ "Intussusception among infants given an oral rotavirus vaccine". The New England Journal of Medicine 344 (8): 564–572. February 2001. doi:10.1056/NEJM200102223440804. PMID 11207352. 
  28. ↑ "Population-based study of rotavirus vaccination and intussusception". The Pediatric Infectious Disease Journal 20 (4): 410–416. April 2001. doi:10.1097/00006454-200104000-00008. PMID 11332666. 
  29. ↑ Centers for Disease Control and Prevention (CDC) (September 2004). "Suspension of rotavirus vaccine after reports of intussusception--United States, 1999". MMWR. Morbidity and Mortality Weekly Report 53 (34): 786–789. PMID 15343145. 
  30. ↑ "The pentavalent rotavirus vaccine, RotaTeq". Seminars in Pediatric Infectious Diseases 17 (4): 195–199. October 2006. doi:10.1053/j.spid.2006.08.005. PMID 17055370. 
  31. ↑ "Global Advisory Committee on Vaccine Safety, 11–12 December 2013". Relevé Épidémiologique Hebdomadaire 89 (7): 53–60. February 2014. PMID 24707510. 
  32. ↑ 32.0 32.1 U.S. Food and Drug Administration. "Update on Recommendations for the Use of Rotavirus Vaccines". https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm212140.htm. 
  33. ↑ "Rotarix Vaccine Suspension Lifted". FDA's MedWatch Safety Alerts. May 2010. https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm213978.htm#Rotarix%20Vaccine%20Suspension%20Lifted. 
  34. ↑ Clinical trial number Double-blind, Placebo-controlled Phase III Clinical Trial to Assess the Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis Among Infants in Niger NCT02145000\Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Assess the Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis Among Infants in Niger at ClinicalTrials.gov
  35. ↑ "Rotavirus vaccine could save lives of almost 500,000 children a year". The Guardian. 22 March 2017. ISSN 0261-3077. https://www.theguardian.com/global-development/2017/mar/22/rotavirus-vaccine-could-save-lives-of-almost-500000-children-a-year. 
  36. ↑ "Rotavirus vaccination tied to lower rates of type 1 diabetes". Reuters. 22 January 2019. https://www.reuters.com/article/us-health-diabetes-rotavirus-idUSKCN1PG2L8. 
  37. ↑ "Rotavirus Vaccine May Protect Against Type 1 Diabetes". The New York Times. 30 January 2019. ISSN 0362-4331. https://www.nytimes.com/2019/01/30/well/live/rotavirus-vaccine-may-protect-against-type-1-diabetes.html. 

Further reading

External links

fr:Rotavirus#Vaccins



Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:Rotavirus_vaccine&oldid=3274761"